The effects of cannabis among adults with chronic painandan overview of general harms a systematic review

Annals of Internal Medicine

Volumn 167, Issue 5, 2017, Pages 319-331

  Nugent, Shannon M ^a   Morasco, Benjamin J ^a   O'Neil, Maya E ^a   Freeman, Michele ^a   Low, Allison ^a   Kondo, Karli ^a   Elven, Camille ^a   Zakher, Bernadette ^b   Motu'apuaka, Makalapua ^a   Paynter, Robin ^a   Kansagara, Devan ^a  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIS; MEDICAL CANNABIS;

ABDOMINAL PAIN; ADVERSE OUTCOME; AGITATION; CANCER PAIN; CANNABIS USE; CHRONIC PAIN; COGNITIVE DEFECT; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; FIBROMYALGIA; HUMAN; INFLAMMATORY PAIN; MULTIPLE SCLEROSIS; NEUROPATHIC PAIN; PARANOIA; PATIENT HARM; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SIDE EFFECT; SUICIDE ATTEMPT; SYSTEMATIC REVIEW; TRAFFIC ACCIDENT; ADULT; NEURALGIA; PATHOPHYSIOLOGY; PSYCHOSES, SUBSTANCE-INDUCED; QUALITY OF LIFE;

ACCIDENTS, TRAFFIC; ADULT; CANCER PAIN; CHRONIC PAIN; HUMANS; MEDICAL MARIJUANA; MULTIPLE SCLEROSIS; NEURALGIA; PSYCHOSES, SUBSTANCE-INDUCED; QUALITY OF LIFE;

EID: 85028829650     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M17-0155     Document Type: Review

References (100)

1. Ryan-Ibarra S, Induni M, Ewing D. Prevalence of medical marijuana use in California, 2012. Drug Alcohol Rev. 2015;34:141-6. [PMID: 25255903] doi:10. 1111/dar. 12207
2. Adler JN, Colbert JA. Clinical decisions. Medicinal use of marijuana-polling results. N Engl J Med. 2013;368:e30. [PMID: 23718175] doi:10. 1056/NEJMclde1305159
3. National Conference of State Legislatures. Marijuana Overview. Accessed at www. ncsl. org/research/civil-and-criminal-justice/marijuana-overview. aspx on 19 May 2017.
4. Bonn-Miller MO, Boden MT, Bucossi MM, Babson KA. Selfreported cannabis use characteristics, patterns and helpfulness among medical cannabis users. Am J Drug Alcohol Abuse. 2014;40: 23-30. [PMID: 24205805] doi:10. 3109/00952990. 2013. 821477
5. Ilgen MA, Bohnert K, Kleinberg F, Jannausch M, Bohnert AS, Walton M, et al. Characteristics of adults seeking medical marijuana certification. Drug Alcohol Depend. 2013;132:654-9. [PMID: 23683791] doi:10. 1016/j. drugalcdep. 2013. 04. 019
6. Degenhardt L, Lintzeris N, Campbell G, Bruno R, Cohen M, Farrell M, et al. Experience of adjunctive cannabis use for chronic noncancer pain: findings from the Pain and Opioids IN Treatment (POINT) study. Drug Alcohol Depend. 2015;147:144-50. [PMID: 25533893] doi:10. 1016/j. drugalcdep. 2014. 11. 031
7. Reisfield GM, Wasan AD, Jamison RN. The prevalence and significance of cannabis use in patients prescribed chronic opioid therapy: a review of the extant literature. Pain Med. 2009;10:1434-41. [PMID: 19793342] doi:10. 1111/j. 1526-4637. 2009. 00726. x
8. Kansagara D, O'Neil M, Nugent S, Freeman M, Low A, Kondo K, et al. Benefits and harms of cannabis in chronic pain or posttraumatic stress disorder: a systematic review. Washington, DC: U. S. Department of Veterans Affairs; 2016. VA ESP project no. 05-225.
9. Kansagara D, O'Neil ME, Morasco B, Madore S, Elven C, Freeman M, et al. Cannabis for the management of symptoms of chronic pain and/or PTSD. Accessed at www. crd. york. ac. uk/prospero/display-record. aspID=CRD42016033623 on 19 May 2017.
10. Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313:2456-73. [PMID: 26103030] doi:10. 1001/jama. 2015. 6358
11. Butler M, Krebs E, Sunderlin B, Kane R. Medical cannabis for non-cancer pain: a systematic review. Accessed at www. health. state. mn. us/topics/cannabis/intractable/medicalcannabisreport. pdf on 19 May 2017.
12. Oregon Health Authority. Medical Marijuana Rules and Statutes. Accessed at https://public. health. oregon. gov/DiseasesConditions /ChronicDisease/MedicalMarijuanaProgram/Pages/legal. aspx on 19 May 2017.
13. Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol. 2007;7:10. [PMID: 17302989]
14. Higgins JPT, Altman DG, Sterne JAC, on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5. 1. 0. The Cochrane Collaboration; 2011. Accessed at www. handbook. cochrane. org on 19 May 2017.
15. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Accessed at www. ohri. ca /programs/clinical-epidemiology/oxford. asp on 19 May 2017.
16. Viswanathan M, Ansari M, Berkman N, Chang S, Hartling L, McPheeters L, et al. Assessing the Risk of Bias of Individual Studies in Systematic Reviews of Health Care Interventions. Rockville: Agency for Healthcare Research and Quality; 2012. AHRQ publication no. 12-EHC047-EF. (Methods Guide for Comparative Effectiveness Reviews). Accessed at www. effectivehealthcare. ahrq. gov/ehc /products/322/998/MethodsGuideforCERs-Viswanathan-Individual Studies. pdf on 19 May 2017.
17. Hardy RJ, Thompson SG. A likelihood approach to meta-analysis with random effects. Stat Med. 1996;15:619-29. [PMID: 8731004]
18. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-60. [PMID: 12958120]
19. Berkman N, Lohr K, Ansari M, McDonagh M, Balk E, Whitlock E, et al. Grading the Strength of a Body of Evidence When Assessing Health Care Interventions for the Effective Health Care Program of the Agency for Healthcare Research and Quality: An Update. Rockville: Agency for Healthcare Research and Quality; 2013. AHRQ publication no. 13(14)-EHC130-EF. (Methods Guide for Comparative Effectiveness Reviews). Accessed at www. effectivehealthcare. ahrq. gov/ehc/products/457/1752/methods-guidance-grading-evidence-131118. pdf on 19 May 2017.
20. Atkins D, Chang S, Gartlehner G, Buckley D, Whitlock E, Berliner E, et al. Assessing the Applicability of Studies When Comparing Medical Interventions. Rockville: Agency for Healthcare Research and Quality; 2013. AHRQ publication no. 11-EHC019-EF. (Methods Guide for Comparative Effectiveness Reviews). Accessed at www. effectivehealthcare. ahrq. gov/ehc/products/272/603/Methods%20 Guide-Atkins-01-03-2011KM. pdf on 19 May 2017.
21. Blake DR, Robson P, Ho M, Jubb RW, McCabe CS. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford). 2006;45:50-2. [PMID: 16282192]
22. Collin C, Ehler E, Waberzinek G, Alsindi Z, Davies P, Powell K, et al. A double-blind, randomized, placebo-controlled, parallelgroup study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res. 2010;32:451-9. [PMID: 20307378] doi: 10. 1179/016164109X12590518685660
23. Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT. Multicenter, double-blind, randomized, placebocontrolled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage. 2010;39:167-79. [PMID: 19896326] doi:10. 1016/j. jpainsymman. 2009. 06. 008
24. Lynch ME, Cesar-Rittenberg P, Hohmann AG. A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapyinduced neuropathic pain. J Pain Symptom Manage. 2014;47:166-73 [PMID: 23742737] doi:10. 1016/j. jpainsymman. 2013. 02. 018
25. Portenoy RK, Ganae-Motan ED, Allende S, Yanagihara R, Shaiova L, Weinstein S, et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebocontrolled, graded-dose trial. J Pain. 2012;13:438-49. [PMID: 22483680] doi:10. 1016/j. jpain. 2012. 01. 003
26. Selvarajah D, Gandhi R, Emery CJ, Tesfaye S. Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor. Diabetes Care. 2010;33:128-30. [PMID: 19808912] doi:10. 2337/dc09-1029
27. Serpell M, Ratcliffe S, Hovorka J, Schofield M, Taylor L, Lauder H, et al. A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. Eur J Pain. 2014;18:999-1012. [PMID: 24420962] doi:10. 1002 /j. 1532-2149. 2013. 00445. x
28. Wilsey B, Marcotte T, Tsodikov A, Millman J, Bentley H, Gouaux B, et al. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain. 2008;9:506-21. [PMID: 18403272] doi:10. 1016/j. jpain. 2007. 12. 010
29. Zajicek JP, Hobart JC, Slade A, Barnes D, Mattison PG; MUSEC Research Group. Multiple sclerosis and extract of cannabis: results of the MUSEC trial. J Neurol Neurosurg Psychiatry. 2012;83:1125-32. [PMID: 22791906] doi:10. 1136/jnnp-2012-302468
30. Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain. 2004; 112:299-306. [PMID: 15561385]
31. Ellis RJ, Toperoff W, Vaida F, van den Brande G, Gonzales J, Gouaux B, et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology. 2009;34:672-80. [PMID: 18688212] doi:10. 1038/npp. 2008. 120
32. Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, et al; UK MS Research Group. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet. 2003;362: 1517-26. [PMID: 14615106]
33. Abrams DI, Jay CA, Shade SB, Vizoso H, Reda H, Press S, et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology. 2007;68:515-21. [PMID: 17296917]
34. Noyes R Jr, Brunk SF, Avery DA, Canter AC. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther. 1975;18:84-9. [PMID: 50159]
35. Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain. 2007;133:210-20. [PMID: 17997224]
36. Wallace MS, Marcotte TD, Umlauf A, Gouaux B, Atkinson JH. Efficacy of Inhaled Cannabis on Painful Diabetic Neuropathy. J Pain. 2015;16:616-27. [PMID: 25843054] doi:10. 1016/j. jpain. 2015. 03. 008
37. Corey-Bloom J, Wolfson T, Gamst A, Jin S, Marcotte TD, Bentley H, et al. Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. CMAJ. 2012;184:1143-50. [PMID: 22586334] doi:10. 1503/cmaj. 110837
38. Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler. 2004;10:434-41 [PMID: 15327042]
39. Ware MA, Wang T, Shapiro S, Robinson A, Ducruet T, Huynh T, et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ. 2010;182:E694-701. [PMID: 20805210] doi: 10. 1503/cmaj. 091414
40. Wilsey B, Marcotte T, Deutsch R, Gouaux B, Sakai S, Donaghe H. Low-dose vaporized cannabis significantly improves neuropathic pain. J Pain. 2013;14:136-48. [PMID: 23237736] doi:10. 1016/j. jpain. 2012. 10. 009
41. Langford RM, Mares J, Novotna A, Vachova M, Novakova I, Notcutt W, et al. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. J Neurol. 2013;260: 984-97. [PMID: 23180178] doi:10. 1007/s00415-012-6739-4
42. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005;65:812-9. [PMID: 16186518]
43. Notcutt W, Price M, Miller R, Newport S, Phillips C, Simmons S, et al. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies. Anaesthesia. 2004;59: 440-52. [PMID: 15096238]
44. Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil. 2003; 17:21-9. [PMID: 12617376]
45. van Amerongen G, Kanhai K, Baakman AC, Heuberger J, Klaassen E, Beumer TL, et al. Effects on spasticity and neuropathic pain of an oral formulation of 9-tetrahydrocannabinol in patients with progressive multiple sclerosis. Clin Ther. 2017. [PMID: 28189366] doi: 10. 1016/j. clinthera. 2017. 01. 016
46. de Vries M, van Rijckevorsel DC, Vissers KC, Wilder-Smith OH, van Goor H; Pain and Nociception Neuroscience Research Group. Tetrahydrocannabinol does not reduce pain in patients with chronic abdominal pain in a phase 2 placebo-controlled study. Clin Gastroenterol Hepatol. 2016. [PMID: 27720917] doi:10. 1016/j. cgh. 2016. 09. 147
47. Wilsey B, Marcotte TD, Deutsch R, Zhao H, Prasad H, Phan A. An exploratory human laboratory experiment evaluating vaporized cannabis in the treatment of neuropathic pain from spinal cord injury and disease. J Pain. 2016;17:982-1000. [PMID: 27286745] doi:10. 1016/j. jpain. 2016. 05. 010
48. Fiz J, Durán M, Capellà D, Carbonell J, Farré M. Cannabis use in patients with fibromyalgia: effect on symptoms relief and healthrelated quality of life. PLoS One. 2011;6:e18440. [PMID: 21533029] doi:10. 1371/journal. pone. 0018440
49. Storr M, Devlin S, Kaplan GG, Panaccione R, Andrews CN. Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with Crohn's disease. Inflamm Bowel Dis. 2014;20:472-80. [PMID: 24407485] doi:10. 1097/01. MIB. 0000440982. 79036. d6
50. Ware MA, Wang T, Shapiro S, Collet JP; COMPASS study team. Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS). JPain. 2015;16:1233-42. [PMID:26385201]doi:10. 1016/j. jpain. 2015. 07. 014
51. Rogeberg O, Elvik R. The effects of cannabis intoxication on motor vehicle collision revisited and revised. Addiction. 2016;111:1348-59 [PMID: 26878835] doi:10. 1111/add. 13347
52. Hancox RJ, Poulton R, Ely M, Welch D, Taylor DR, McLachlan CR, et al. Effects of cannabis on lung function: a population-based cohort study. Eur Respir J. 2010;35:42-7. [PMID: 19679602] doi:10. 1183/ 09031936. 00065009
53. Pletcher MJ, Vittinghoff E, Kalhan R, Richman J, Safford M, Sidney S, et al. Association between marijuana exposure and pulmonary function over 20 years. JAMA. 2012;307:173-81. [PMID: 22235088] doi:10. 1001/jama. 2011. 1961
54. Tetrault JM, Crothers K, Moore BA, Mehra R, Concato J, Fiellin DA. Effects of marijuana smoking on pulmonary function and respi ratory complications: a systematic review. Arch Intern Med. 2007; 167:221-8. [PMID: 17296876]
55. Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE. Triggering myocardial infarction by marijuana. Circulation. 2001; 103:2805-9. [PMID: 11401936]
56. Frost L, Mostofsky E, Rosenbloom JI, Mukamal KJ, Mittleman MA. Marijuana use and long-term mortality among survivors of acute myocardial infarction. Am Heart J. 2013;165:170-5. [PMID: 23351819] doi:10. 1016/j. ahj. 2012. 11. 00757.
57. Zhang LR, Morgenstern H, Greenland S, Chang SC, Lazarus P, Teare MD, et al; Cannabis and Respiratory Disease Research Group of New Zealand. Cannabis smoking and lung cancer risk: pooled analysis in the International Lung Cancer Consortium. Int J Cancer. 2015;136:894-903. [PMID: 24947688] doi:10. 1002/ijc. 29036
58. Callaghan RC, Allebeck P, Sidorchuk A. Marijuana use and risk of lung cancer: a 40-year cohort study. Cancer Causes Control. 2013; 24:1811-20. [PMID: 23846283] doi:10. 1007/s10552-013-0259-0
59. de Carvalho MF, Dourado MR, Fernandes IB, Araú jo CT, Mesquita AT, Ramos-Jorge ML. Head and neck cancer among marijuana users: a meta-analysis of matched case-control studies. Arch Oral Biol. 2015;60:1750-5. [PMID: 26433192] doi:10. 1016/j. archoralbio. 2015. 09. 009
60. Gurney J, Shaw C, Stanley J, Signal V, Sarfati D. Cannabis exposure and risk of testicular cancer: a systematic review and metaanalysis. BMC Cancer. 2015;15:897. [PMID: 26560314] doi:10. 1186 /s12885-015-1905-6
61. Chacko JA, Heiner JG, Siu W, Macy M, Terris MK. Association between marijuana use and transitional cell carcinoma. Urology. 2006;67:100-4. [PMID: 16413342]
62. Borges G, Bagge CL, Orozco R. A literature review and metaanalyses of cannabis use and suicidality. J Affect Disord. 2016;195: 63-74. [PMID: 26872332] doi:10. 1016/j. jad. 2016. 02. 007
63. Gibbs M, Winsper C, Marwaha S, Gilbert E, Broome M, Singh SP. Cannabis use and mania symptoms: a systematic review and metaanalysis. J Affect Disord. 2015;171:39-47. [PMID: 25285897] doi:10. 1016/j. jad. 2014. 09. 016
64. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007;370:319-28. [PMID: 17662880]
65. Kuepper R, van Os J, Lieb R, Wittchen HU, Höfler M, Henquet C. Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. BMJ. 2011; 342:d738. [PMID: 21363868] doi:10. 1136/bmj. d738
66. Dominguez MD, Saka MC, can Saka M, Lieb R, Wittchen HU, van Os J. Early expression of negative/disorganized symptoms predicting psychotic experiences and subsequent clinical psychosis: a 10-year study. Am J Psychiatry. 2010;167:1075-82. [PMID: 20634371] doi:10. 1176/appi. ajp. 2010. 09060883
67. Rössler W, Hengartner MP, Angst J, Ajdacic-Gross V. Linking substance use with symptoms of subclinical psychosis in a community cohort over 30 years. Addiction. 2012;107:1174-84. [PMID: 22151745] doi:10. 1111/j. 1360-0443. 2011. 03760. x
68. Kaufmann RM, Kraft B, Frey R, Winkler D, Weiszenbichler S, Bäcker C, et al. Acute psychotropic effects of oral cannabis extract with a defined content of Delta9-tetrahydrocannabinol (THC) in healthy volunteers. Pharmacopsychiatry. 2010;43:24-32. [PMID: 20178093] doi:10. 1055/s-0029-1237397
69. Englund A, Morrison PD, Nottage J, Hague D, Kane F, Bonaccorso S, et al. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol. 2013;27:19-27. [PMID: 23042808] doi:10. 1177 /0269881112460109
70. Di Forti M, Morgan C, Dazzan P, Pariante C, Mondelli V, Marques TR, et al. High-potency cannabis and the risk of psychosis. Br J Psychiatry. 2009;195:488-91. [PMID: 19949195] doi:10. 1192/bjp. bp. 109. 064220
71. van Nierop M, Janssens M, Bruggeman R, Cahn W, de Haan L, Kahn RS, et al; Genetic Risk OUtcome of Psychosis Investigators. Evidence that transition from health to psychotic disorder can be traced to semi-ubiquitous environmental effects operating against background genetic risk. PLoS One. 2013;8:e76690. [PMID: 24223116] doi:10. 1371/journal. pone. 0076690
72. Schreiner AM, Dunn ME. Residual effects of cannabis use on neurocognitive performance after prolonged abstinence: a meta-analysis. Exp Clin Psychopharmacol. 2012;20:420-9. [PMID: 22731735] doi:10. 1037/a0029117
73. Ganzer F, Bröning S, Kraft S, Sack PM, Thomasius R. Weighing the evidence: a systematic review on long-term neurocognitive effects of cannabis use in abstinent adolescents and adults. Neuropsychol Rev. 2016;26:186-222. [PMID: 27125202] doi:10. 1007/s11065-016-9316-2
74. Mason O, Morgan CJ, Dhiman SK, Patel A, Parti N, Patel A, et al. Acute cannabis use causes increased psychotomimetic experiences in individuals prone to psychosis. Psychol Med. 2009;39:951-6. [PMID: 19017430] doi:10. 1017/S0033291708004741
75. Ramos S, Rodrigues R, Almeida N, Sá JM, Fonseca L. Cannabinoid hyperemesis syndrome [Abstract]. Psychother Psychosom. 2013;82(Suppl 1):90. Abstract no. 357.
76. Sadiq M. Cannabis hyperemesis syndrome [Abstract]. J Addict Med. 2013;7(Suppl):E3. doi:10. 1097/ADM. 0b013e3182a3b16f
77. Soriano-Co M, Batke M, Cappell MS. The cannabis hyperemesis syndrome characterized by persistent nausea and vomiting, abdominal pain, and compulsive bathing associated with chronic marijuana use: a report of eight cases in the United States. Dig Dis Sci. 2010; 55:3113-9. [PMID: 20130993] doi:10. 1007/s10620-010-1131-7
78. Velasco A, Pentecost P. An unexpected etiology of cyclical vomiting [Abstract]. J Hosp Med. 2012;7(suppl2). Abstract no. 97987.
79. Vujasinovic M, Ivartnik M, Tretjak M. Cannabinoid hyperemesis syndrome-case report. Zdravniski vestnik. 2012;81:159-62. doi:10. 6016/722
80. Welder JD. Some like it hot: a case of cannabinoid hyperemesis syndrome [Abstract]. J Gen Intern Med. 2012;27:S480-1.
81. Woods JA, Wright NJ, Gee J, Scobey MW. Cannabinoid hyperemesis syndrome: an emerging drug-induced disease. Am J Ther. 2016;23:e601-5. [PMID: 24413371] doi:10. 1097/MJT. 0000000000000034
82. Sorensen CJ, DeSanto K, Borgelt L, Phillips KT, Monte AA. Cannabinoid hyperemesis syndrome: diagnosis, pathophysiology, and treatment-a systematic review. J Med Toxicol. 2017;13:71-87. [PMID: 28000146] doi:10. 1007/s13181-016-0595-z
83. Cescon DW, Page AV, Richardson S, Moore MJ, Boerner S, Gold WL. Invasive pulmonary aspergillosis associated with marijuana use in a man with colorectal cancer. J Clin Oncol. 2008;26:2214-5. [PMID: 18445848] doi:10. 1200/JCO. 2007. 15. 2777
84. Chusid MJ, Gelfand JA, Nutter C, Fauci AS. Letter: Pulmonary aspergillosis, inhalation of contaminated marijuana smoke, chronic granulomatous disease. Ann Intern Med. 1975;82:682-3. [PMID: 1094876]
85. Marks WH, Florence L, Lieberman J, Chapman P, Howard D, Roberts P, et al. Successfully treated invasive pulmonary aspergillosis associated with smoking marijuana in a renal transplant recipient. Transplantation. 1996;61:1771-4. [PMID: 8685958]
86. Institute of Medicine Committee on Advancing Pain Research, Care, and Education. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Washington, DC: National Academies Pr; 2011.
87. Munckhof WJ, Konstantinos A, Wamsley M, Mortlock M, Gilpin C. A cluster of tuberculosis associated with use of a marijuana water pipe. Int J Tuberc Lung Dis. 2003;7:860-5. [PMID: 12971670]
88. Oeltmann JE, Oren E, Haddad MB, Lake Lk, Harrington TA, Ijaz K, et al. Tuberculosis outbreak in marijuana users, Seattle, Washington, 2004. Emerg Infect Dis. 2006;12:1156-9. [PMID: 16836841]
89. Carabellese F, Candelli C, Martinelli D, La Tegola D, Catanesi R. Cannabis use and violent behaviour: a psychiatric patients cohort study in Southern Italy. Riv Psichiatr. 2013;48:43-50. [PMID: 23438700] doi:10. 1708/1228. 13614
90. Myerscough R, Taylor S. The effects of marijuana on human physical aggression. J Pers Soc Psychol. 1985;49:1541-6. [PMID: 3003332]
91. Blanco C, Hasin DS, Wall MM, Flórez-Salamanca L, Hoertel N, Wang S, et al. Cannabis use and risk of psychiatric disorders: prospective evidence from a US national longitudinal study. JAMA Psychiatry. 2016;73:388-95. [PMID: 26886046] doi:10. 1001 /jamapsychiatry. 2015. 3229
92. Fleming MF, Balousek SL, Klessig CL, Mundt MP, Brown DD. Substance use disorders in a primary care sample receiving daily opioid therapy. J Pain. 2007;8:573-82. [PMID: 17499555]
93. National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: National Academies Pr; 2017. doi:10. 17226/24625
94. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain-United States, 2016. MMWR Recomm Rep. 2016;65:1-49. [PMID: 26987082] doi:10. 15585/mmwr. rr6501e1
95. Abrams DI, Couey P, Shade SB, Kelly ME, Benowitz NL. Cannabinoid-opioid interaction in chronic pain. Clin Pharmacol Ther. 2011;90:844-51. [PMID: 22048225] doi:10. 1038/clpt. 2011. 188
96. DeGeorge M, Dawson E, Woster P, Ko M, Burke L, Bronstein K. An analysis of the association between marijuana use and potential nonadherence in patients prescribed hydrocodone. Proceedings of the 2013 annual meeting of the American Academy of Pain Medicine. Fort Lauderdale, FL: 2013, April. Poster Abstract 114. Accessed at www. painmed. org/2013posters/poster114. pdf on 19 May 2017.
97. Hefner K, Sofuoglu M, Rosenheck R. Concomitant cannabis abuse/dependence in patients treated with opioids for non-cancer pain. Am J Addict. 2015;24:538-45. [PMID: 26246069] doi:10. 1111 /ajad. 12260
98. Ashrafioun L, Bohnert KM, Jannausch M, Ilgen MA. Characteristics of substance use disorder treatment patients using medical cannabis for pain. Addict Behav. 2015;42:185-8. [PMID: 25481452] doi: 10. 1016/j. addbeh. 2014. 11. 024
99. Haroutounian S, Ratz Y, Ginosar Y, Furmanov K, Saifi F, Meidan R, et al. The effect of medicinal cannabis on pain and quality-of-life outcomes in chronic pain: a prospective open-label study. Clin J Pain. 2016;32:1036-1043. [PMID: 26889611]
100. Vandrey R, Raber JC, Raber ME, Douglass B, Miller C, Bonn-Miller MO. Cannabinoid dose and label accuracy in edible medical cannabis products. JAMA. 2015;313:2491-3. [PMID: 26103034] doi: 10. 1001/jama. 2015. 6613